Researchers announced on Saturday an experimental drug that significantly reduces the negative effects of heart failure. Some are calling it "one of the biggest potential advances" against the disease in more than 10 years.
Currently called LCZ696, the drug is being developed by Swiss pharmaceutical company Novartis, according to a study in the New England Journal of Medicine. A release from Novartis suggested that LCZ696 cut the risk of death and hospitalization from heart failure by a fifth, and measurably improved patients' quality of life.
"By demonstrating a very significant reduction in cardiovascular deaths while improving quality of life, Novartis' new heart failure medicine, LCZ696, represents one of the most important cardiology advances of the last decade," David Epstein, division head of Novartis said in a release.
LCZ696 is a twice-a-day pill that combines two active medications that work to block negative substances that harm heart function, and enable substances that enhance it, according to the release. The pill also reportedly dilates the heart's blood vessels, improving its ability to pump blood to the body.
New Drug Makes Strides in Heart Failure Treatment, Study Says